Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) [Phase 2]

View source ↗

Summary

The National Cancer Institute’s MATCH subprotocol R Phase 2 trial is evaluating trametinib as a targeted therapy for cancers with BRAF genetic alterations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Lymphoma
• Malignant Solid Tumor
• Multiple Myeloma

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-03-03